<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01325259</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN08-VC / FAIR AD</org_study_id>
    <nct_id>NCT01325259</nct_id>
  </id_info>
  <brief_title>FluoroAv45 Imaging Research-in Alzheimer's Disease</brief_title>
  <acronym>FAIR-AD</acronym>
  <official_title>Molecular Imaging of Cerebral Amyloid Plaques Using PET With Fluoro Tracker for Early Diagnosis of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: improving the early detection of AD at prodromal pre-dementia stages has become a
      major matter of concern. There is now an important body of literature stating that early
      isolated cognitive deficits (Mild Cognitive Impairment-MCI-) predict the risk of developing
      AD. Several biomarkers are now available : specific and sensitive neuropsychological
      assessments, morphometric evaluation of hippocampal volume and white matter changes by MRI,
      cerebrospinal fluid or plasma dosage of Ab fragments and tau proteins, assessment of brain
      glucose hypometabolism in temporo-parietal regions with PET [F18]FDG. However, PET imaging
      using labelled compounds specifically binding to APs has been suggested to improve the
      diagnostic reliability and to potentially help in shortening the delay until formal clinical
      diagnosis of AD. F18 AV45 is a new radiotracer which kinetics characteristics allows 10 to 15
      minutes acquisition 50 to 60 minutes post injection.

      Objectives: The primary objective of the study is to compare F18 AV45 cortical uptake in AD,
      MCI patients and Healthy Controls.

      Secondary objectives will be to compare cortical uptake of F18 AV45 in MCI subject who will
      have convert toward dementia versus those who will not, at two year follow-up period, to
      compare level of 18F-AV45 cortical uptake with neuropsychological testing, PET FDG
      hypometabolism, ApoE genotype.

      Method: Prospective multicentric study. 65 patients expected to enter the study.

      Primary outcome measure: Standard Uptake Volume ratios.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standard Uptake Value Ratios (SUVr)</measure>
    <time_frame>inclusion</time_frame>
    <description>Standard Uptake Value Ratios (SUVr) in specific regions of interest (ROI) defined by the use of the cerebellum as reference region.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients suffering from Alzheimer's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients suffering from Mild Cognitive Impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 subjects with no cognitive impairment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychologic assessment</intervention_name>
    <description>Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]AV-45 PET</intervention_name>
    <description>intravenous injection of 4 MBq/kg of [18F]AV-45</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>18-FDG PET</intervention_name>
    <description>intravenous injection of 100 to 120 MBq of FDG</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Magnetic Resonance Imaging</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Mild Cognitive Impairment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from Alzheimer's Disease (NINCDS-ADRDA) or from amnesic MCI

          -  18 &lt; MMS &lt;= 28 for patients

          -  28 &lt;= MMS for healthy volunteers

          -  study period &gt; 7 years

          -  native language : french

          -  signed informed consent

          -  affiliated to a social security system

        Exclusion Criteria:

          -  alcoholism in medical history

          -  diabetes

          -  arterial hypertension (180/100 and more)

          -  chronical pulmonary disease with hypoxis

          -  cranial traumatism with loss of consciousness &gt; 15 minutes

          -  severe depressive syndrome or anxiety

          -  psychiatric disease in medical history (excepted simple episodes of depression)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Camus</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>university hospital of CAEN</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2011</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

